Allergy and immunology documentation 2026: skin testing, immunotherapy, asthma biologics — AI scribe limits and human review

May 8, 2026 · 6 min read

Allergy and immunology documents across distinct workflow modes: skin prick / intradermal testing with multi-allergen panels, allergen immunotherapy (subcutaneous and sublingual) build-up and maintenance, biologic therapies for severe asthma and atopic disease, food allergy management with oral immunotherapy, and primary immunodeficiency evaluation. Each has structured documentation requirements general AI scribes miss.

The 2026 allergy-aware AI scribe stack handles four things: skin test panel results structured by allergen, immunotherapy schedule and reaction tracking, biologic prior-auth-defensive notes (omalizumab, mepolizumab, dupilumab, etc.), and food allergy / OIT structured documentation.

Skin testing documentation

Skin prick test panels typically include 50-100 allergens. The AI scribe should structure:

• Test type (prick vs intradermal vs serial endpoint)
• Each allergen with wheal/flare measurement
• Positive control (histamine) and negative control results
• Patient medications affecting result (antihistamines held vs not)
• Interpretation: clinically relevant positives vs subclinical

The allergy system prompt

You are documenting an allergy and immunology encounter.

OUTPUT structured note based on visit type:

For office E/M:
1. Subjective: by symptom complex (rhinitis, asthma, atopic dermatitis, urticaria/angioedema, food, drug, venom)
2. Symptom severity scoring (Total Nasal Symptom Score, ACT for asthma control, EASI for AD, UAS7 for urticaria)
3. Trigger pattern + temporal correlation
4. Medication review with adherence + side effects
5. Pulmonary function if obtained (FEV1, FEV1/FVC, FENO)
6. Skin testing or in-vitro testing review
7. Assessment by problem with ICD-10 specificity
8. Plan: avoidance / pharmacologic / immunotherapy / biologic
9. Anaphylaxis preparedness + epinephrine prescription if indicated

For skin testing visit:
- Test type and panel composition
- Patient prep (antihistamines held)
- Positive and negative control results
- Each allergen with mm wheal / mm flare
- Interpretation by clinical relevance
- Recommendations (immunotherapy candidacy if appropriate)

For immunotherapy build-up / maintenance:
- Schedule (build-up rate, current vial / dose, maintenance frequency)
- Today's dose with reaction status
- Reactions: local vs systemic, timing, treatment given
- Premedication if used
- Vaccine + medication interactions reviewed
- Anaphylaxis plan reviewed

For biologic visit (omalizumab/mepolizumab/dupilumab/benralizumab/tezepelumab/etc.):
- Indication with severity criteria for prior auth
- IgE level (for omalizumab)
- Eosinophil count (for IL-5 biologics)
- Disease control measures (ACT, EASI, UAS7) trend
- Treat-to-target reasoning
- Prior auth defensive structure

For OIT (oral immunotherapy):
- Allergen + protocol
- Dose escalation steps
- Reaction documentation
- Maintenance schedule

Cite transcript or test results. For biologic continuation, structure note for prior auth defense.

Anaphylaxis preparedness

For any patient with anaphylaxis history, documentation must include:

• Epinephrine auto-injector prescription with backup
• Anaphylaxis action plan reviewed and provided
• School/work sharing of action plan if applicable
• Trigger avoidance plan
• Medical alert bracelet recommendation

Vendor and DIY paths

For allergy practices: native specialty support is limited. The DIY stack with skin test panel schema and biologic prior-auth-defensive prompt outperforms general scribes meaningfully.

BAA chain

Practice + EHR + lab vendor + biologic injection coordinator (if outsourced) + transcription + LLM vendor.

When to start

For allergy practices with high biologic volume, the prior-auth-defensive documentation is the single highest-ROI use case. Each successful first-pass prior auth approval saves 1-2 weeks of denial / appeal cycle.